Major Valeant shareholder Sequoia exits its stake after losses

Valeant

Sequoia Fund, a major Valeant shareholder, has seen enough from the struggling drugmaker.

Ruane, Cunniff & Goldfarb, the fund’s manager and once Valeant’s biggest investor, says it exited its stake in the Canadian pharma last month after sustaining major losses.

“Valeant was our largest position to start the year and its 80% decline through June 30 badly penalized our results,” Ruane Cunniff CEO David Poppe wrote in a letter seen by Bloomberg.

Conference

The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Sequoia, which first picked up Valeant in 2010, has been sharing in Valeant’s hardships since last year, when a short seller piled channel-stuffing allegations on top of a drug-pricing controversy that was already weighing on the stock. Ruane Cunniff did its best to get to the bottom of claims, reaching out to former employees of Valeant-linked specialty pharmacy Philidor and even paying hundreds for information. But Valeant’s downward spiral continued, perpetuating Sequoia’s own slump.

The result? A 7.3% loss last year that spurred the retirement of CEO Robert Goldfarb, who Poppe replaced in March. And investors who claimed Sequoia recklessly took a huge stake in Valeant--which once accounted for more than 30% of its portfolio--slapped the fund with a lawsuit in January. The losses continued in the first half of this year, with the fund losing more than 13%. Without Valeant, it would have gained 2.3% through June, Bloomberg reports.

Sequoia, of course, isn’t the only one that’s been hurt by Valeant’s serious slide. Leading shareholder Bill Ackman’s Pershing Square Capital Management has been badly burned, too, prompting the activist investor to jump into the fray and join the board in an effort to set things straight.

So far, though, the stock is still bottom-feeding, in part thanks to a debt-default worries and a Walgreens distribution deal new CEO Joseph Papa has said is hurting sales. The skipper has said he’s working on correcting both, though, potentially through asset sales and a renegotiated Walgreens pact.

- get more from Bloomberg

Related Articles:
Walgreens 'very willing to help' Valeant fix troubled distribution deal: Execs
With new CEO’s dealmaking and price-hiking past, can Valeant change its spots?​
Activist Ackman vows to intervene after disastrous day at Valeant​
Valeant's meltdown claims another top exec, this time at shareholder Sequoia​
Pharma scandals spawn investor lawsuits at KaloBios, Sequoia​
Valeant employees closely involved with Philidor operations: Reuters

Suggested Articles

For just the second time, the DOJ indicted an opioid distributor for its role in illegally pushing pills at the height of the addiction epidemic.

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.

When AstraZeneca sold its Avlon, England plant in 2016, it thought its liabilities were over. Former employees said the drugmaker broke its promises.